<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="medicina-56-00386-t003" orientation="portrait" position="float">
 <object-id pub-id-type="pii">medicina-56-00386-t003_Table 3</object-id>
 <label>Table 3</label>
 <caption>
  <p>The algorithm proposal for therapeutic management with antioxidants for COVID-19 patients.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Identification of the Case and Integral Study</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Management by the Intensive Care Specialist</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Proposed Treatment Assays</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Additional Proposed Antioxidant Therapy to the Medical Management in COVID-19 Patients with Pneumonia</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug Interactions</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="5" align="center" valign="top" colspan="1">1. Identification of infected cases having a medical history (healthy or with simple or combined comorbidities), age, body mass index.
     <break/> 2. Integral laboratory tests, including total cholesterol, HDL, LDL, triglycerides, D dimer, troponins, natriuretic peptide, creatine phosphokinase, Cl, Na, K, magnesium, phosphorus. Evaluation of hepatic and renal function.
     <break/> 3. Chest X-ray and/or computerized tomography.
     <break/> 4. Cardiovascular: electrocardiogram, echocardiogram.
     <break/> 5. When a cardiovascular disease is present, a multidisciplinary management involving a cardiologist is suggested (this applies to all cases).
    </td>
    <td rowspan="5" align="center" valign="top" colspan="1">1. Antibiotics, according to requirements. A culture if an associated bacterial infection is present.
     <break/> 2. Mechanical ventilation.
     <break/> 3. Hemodynamic Management.
     <break/> 4. Extracorporeal membrane oxygenation if necessary (this applies to all cases).
    </td>
    <td rowspan="5" align="center" valign="top" colspan="1">The patient may be treated with any of the therapies suggested by the clinical assays in standard doses.
     <break/> Only one or a combination of two antioxidants may be applied.
     <break/> When the pulmonary function is compromised, a combination of NAC and vitamin C is suggested. (This applies to all cases).
    </td>
    <td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">NAC dose: 600 mg/24 h orally or through a nasal enteral tube for 5 days. It should not be used when there is a gastric ulcer or antecedents of asthma or a cysteine allergy.</td>
    <td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Anti-cholinergic drugs, anti-histaminic drugs.</td>
   </tr>
   <tr>
    <td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">MT dose: 5 mg tablet (10 capsules)/24 h orally or through a nasal enteral tube for five days. It is safe and has a low toxicity. It is contraindicated during pregnancy, diabetes mellitus and when a patient has high systemic hypertension of the blood, and care must be taken when it is used together with some antihypertensive drugs.</td>
    <td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Sedatives, Luvox contraceptives and cocaine increase the effect of MT. Verapamil, nifedipine, caffeine, alcohol and immunosuppressors decrease the MT effect.</td>
   </tr>
   <tr>
    <td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Vit C dose: 1 g every 6 h orally or through a nasal enteral tube for 5 days. It should not be used in patients with gastric ulcers, falciform anemia or during pregnancy. At high doses &gt; 3 g, it may interact with medications used in patients with diabetes mellitus, hypertension, or Parkinson’s disease.</td>
    <td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Aluminum, estrogens, protease inhibitors, antivirals: nelfinavir amprenavir, ritonavir, saquinavir, statins, glimepiride, glipizide, metformin, pioglitazone, rosiglitazone, antihypertensive drugs.</td>
   </tr>
   <tr>
    <td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Vit E, dose capsules of 400 UI that are the equivalent of 400 mg every 12 h for 5 days. It should not be used when retinitis pigmentosa is present. </td>
    <td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Simvastatin and niacin, chemotherapy, anticoagulants and antiplatelet agents and non-steroidal anti-inflammatory drugs.</td>
   </tr>
   <tr>
    <td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">QRC, at a dose of 500 mg every 12 h. It is safe for most people, but is not contraindicated during pregnancy. The dose should be adjusted in patients with renal failure. </td>
    <td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Quinolones, uroseptal, cyclosporine, celecoxib, diclofenac, ibuprofen, Fluvastatin, irbesartan, losartan.</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Initial evaluation.
     <break/>
     <inline-graphic xlink:href="medicina-56-00386-i001.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Measures that are jointly evaluated according to the initial evaluation.
     <break/>
     <inline-graphic xlink:href="medicina-56-00386-i002.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Measures that are jointly evaluated according to the initial evaluation.
     <break/>
     <inline-graphic xlink:href="medicina-56-00386-i003.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pentoxifylline (vasodilator, inhibitor of IL-6), at a dose of 400 mg daily orally or IV.
     <break/> Patients that are intolerant to methylxanthines might not tolerate it. (The doses of the elected antioxidants and/or pentoxifylline are similar in all cases.
     <break/> The selection must be taken according to contraindications and drug interactions).
     <break/> Measures that are jointly evaluated according to the initial evaluation.
     <break/>
     <inline-graphic xlink:href="medicina-56-00386-i004.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Coumarin, heparin, indandione derivatives, cefotetan, cefamandole, valproic acid and plicamycin may increase the risk of bleeding.
     <break/> Final evaluation.
     <break/>
     <inline-graphic xlink:href="medicina-56-00386-i005.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/>
    </td>
   </tr>
   <tr>
    <td colspan="5" align="center" valign="top" style="border-bottom:solid thin" rowspan="1">
     <bold>Evaluate and Apply According to the Patient’s Comorbidities</bold>
    </td>
   </tr>
   <tr>
    <td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Diabetes Mellitus with or without Hypertension</bold>
     <break/>NAC or MT or QRC or vit E + pentoxifylline.
    </td>
    <td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Hypertension</bold>
     <break/>NAC or MT (if antihypertensive drugs that may interfere are not being used) or
     <break/>QRC or vit E (if anticoagulants are not being used) or pentoxifylline.
    </td>
    <td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Obesity</bold>
     <break/>
     <bold>Without Another Comorbidity</bold>
     <break/>NAC or MT or QRC or vit E or vit C + pentoxifylline.
     <break/>
     <bold>Obesity + SAH + DM</bold>
     <break/>NAC or QRC + pentoxifylline.
    </td>
    <td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Renal Insufficiency</bold>
     <break/>
     <bold>without Substitute Management</bold>
     <break/>
     <bold>(Dose Adjustment)</bold>
     <break/>NAC or MT or QRC or vit E + pentoxifylline.
     <break/>
     <bold>In Patients in Dialysis of Hemodialysis</bold>
     <break/>Standard dose.
    </td>
    <td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Heart Failure</bold>
     <break/>NAC or MT or QRC or vit E + pentoxifylline.
     <break/>Monitor if the patient uses antiplatelet or anticoagulant digoxin or has an arrhythmia.
    </td>
   </tr>
   <tr>
    <td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Ischemic Heart Disease</bold>
     <break/>NAC or MT or QRC or Vit E + Pentoxifylline
     <break/>Adjust if there is use of antihypertensive drugs that interact with any of them
    </td>
    <td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Myocarditis</bold>
     <break/>NAC or MT or QRC or Vit E + Pentoxifylline
     <break/>
     <bold>On Dialysis or Hemodialysis</bold>
     <break/>Standard dose. Immunoglobulin should be the treatment of choice except contraindication
    </td>
    <td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Arrhythmias</bold>
     <break/>NAC or MT or QRC or + Pentoxifylline
    </td>
    <td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Chronic Obstructive Pulmonary Disease</bold>
     <break/>NAC or MT or QRC or + Pentoxifylline
     <break/>
     <bold>Smoking</bold>
     <break/>NAC or MT or QRC or Vit C + Pentoxifylline
    </td>
    <td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Immune</bold>
     <break/>
     <bold>Suppression</bold>
     <break/>NAC or Vit E (if anticoagulants are not being used) or Pentoxifylline
     <break/>
     <bold>Cancer</bold>
     <break/>NAC or QRC
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>Abbreviations: IV = Intravenous, NAC = N-acetylcysteine, MT = melatonin, QRC = quercetin, vit C = vitamin C, vit E = vitamin E, SAH = systemic arterial hypertension, DM = diabetes mellitus, HDL = high-density lipoprotein, LDL = low-density lipoprotein.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
